FDA Extends Review Of Blood Pressure Drug Tyvaso

SILVER SPRING, Md. (AP) — United Therapeutics Corp. said Tuesday the Food and Drug Administration extended a review of the drug candidate Tyvaso by three months, and now expects to make a ruling by July 30 on the blood pressure treatment.

Tyvaso, or treprostinil, is an inhaled drug intended to treat pulmonary arterial hypertension. United Therapeutics said it submitted new data to the FDA in April, complying with an FDA request, which caused the agency to extend its review period.

In aftermarket trading, shares of United Therapeutics fell 81 cents to $57.25.